Advertisement

Picture [iito] Made Without Love 650x80px
Document › Details

Nabriva Therapeutics plc. (11/6/18). "Press Release: Nabriva Therapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights". Dublin.

Organisations Organisation Nabriva Therapeutics plc (Nasdaq: NBRV)
  Group Nabriva (Group)
  Organisation 2 Zavante Therapeutics Inc.
  Group Nabriva (Group)
Products Product lefamulin (BC-3781)
  Product 2 Contepo™ (fosfomycin for injection, previously ZTI-01 and ZOLYD)
Index term Index term Zavante Therapeutics–Nabriva: investment, 201807 acquisition upfront 8.2m Nabriva ordinary shares (=19.9% shareholding) + $97.5m milestones
Persons Person Schroeder, Ted (Nabriva 201807– CEO before Zavante Therapeutics + Cadence Pharmaceuticals + Élan)
  Person 2 Garrett, Dave (Nabriva 201709 Investor Relations)
     


   
Record changed: 2018-12-25

Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for Nabriva (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture [iito] Back into Ad 650x80px




» top